Clinical Trials Logo

Primary Open Angle Glaucoma clinical trials

View clinical trials related to Primary Open Angle Glaucoma.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 2

NCT ID: NCT04440527 Not yet recruiting - Clinical trials for Primary Open Angle Glaucoma

Intraocular Pressure After Preserflo / Innfocus Microshunt Implantation vs Trabeculectomy

PAINT
Start date: July 22, 2020
Phase: N/A
Study type: Interventional

The aim of this project is to compare trabeculectomy with Preserflo / Innfocus Microshunt in patients with Primary Angle Open Glaucoma and Pseudoexfoliation Glaucoma regarding the reduction of intraocular pressure.

NCT ID: NCT04430296 Not yet recruiting - Clinical trials for Primary Open Angle Glaucoma

Cyclophotocoagulation in Primary Open Angle Glaucoma

Start date: August 1, 2020
Phase: N/A
Study type: Interventional

The use of Cyclodestruction procedures has been extended to patients with non-refractory glaucoma and good vision. Our aim is to compare the safety and efficacy of three cyclodestructive treatments; High Intensity Focused Ultrasound (HIFU) Cyclocoagulation versus micropulse cyclophotocoagulation (MP-CPC) versus transscleral continuous wave cyclophotocoagulation (CW-CPC) for the treatment of Primary open angle glaucoma.

NCT ID: NCT03924544 Not yet recruiting - Clinical trials for Primary Open-angle Glaucoma

Decorin in Sub Scleral Trabeculectomy

Start date: September 1, 2019
Phase: Phase 1
Study type: Interventional

This is a prospective, single-center, interventional, randomized controlled study comparing Decorin as antifibrotic agent in sub scleral trabeculectomy versus Mitomycin.

NCT ID: NCT03762369 Not yet recruiting - Ocular Hypertension Clinical Trials

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Start date: December 7, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate efficacy and safety of CKD-351.

NCT ID: NCT01711177 Not yet recruiting - Clinical trials for Primary Open Angle Glaucoma

Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma

Start date: October 2012
Phase: N/A
Study type: Interventional

Glaucoma is the second leading cause of blindness among seniors in Canada. It is often associated with an elevated intraocular pressure (IOP), but its exact mechanism is still largely unknown. Some studies have shown a link between glaucoma and changes in the amount of oxygen in the veins of the eye. The study aims to compare the amount of oxygen in ocular veins among three different groups using a spectrophotometer. This instrument is linked to a camera and can measure the quantity of oxygen in the veins using different characteristics of the blood inside. The groups of the study are: patients without glaucoma, patients suspected of glaucoma and patients newly diagnosed with glaucoma. The drug the investigators are using, Travoprost 0.004%, will only be administered to the groups suspected or diagnosed with glaucoma. Travoprost 0.004% is already approved for use in Quebec and is part of standard care. Ten patients will be recruited into each group for a total of 30 patients in this study. All patients for the suspected or diagnosed groups will be recruited from the Jewish General Hospital. Subsequently all testing will be done at the École d'optométrie, Université de Montréal

NCT ID: NCT01346904 Not yet recruiting - Clinical trials for Primary Open Angle Glaucoma

a 3.0T Magnetic Resonance Imaging Study

Start date: May 2011
Phase: N/A
Study type: Observational

Glaucomatous damage not only occurred to retinal ganglion cells in the eyes, but went across optic nerves, visual chiasm, lateral geniculate nucleus (LGN) and finally the visual cortex; the neural degenerations could be identified through the whole visual tract, which suggests the central nerve system may play a vital role in the progression of glaucoma. The investigators used MRI to investigate changes of visual pathway in vivo.

NCT ID: NCT00739154 Not yet recruiting - Clinical trials for Primary Open Angle Glaucoma

Protective Effect of Phenytoin on Glaucoma

Start date: November 2008
Phase: N/A
Study type: Observational

since glaucoma is considered an optic neuropathy, new treatments for glaucoma are being continuously investigated, including neuroprotection. Previous studies implied that phenytoin, a potent anti-convulsive drug, has a neuroprotective role, and Na+ channels blockage was suggested as a possible mechanism. This study predicts that glaucoma patients taking Phenytoin will have a less advanced glaucoma as compared to patients not taking the drug. Glaucoma severity will be determined by visual acuity, visual fields, optic disc cupping and nerve fiber layer thickness